Samsung Biologics Co.,Ltd. (207940.KS) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Samsung Biologics Co.,Ltd., built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track 207940.KS live on Mooboard →

31–90 days1

  • Dec 14, 2026
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Intensity modulated radiotherapy · Phase 3 · Prostate Neoplasm
    NCT03241537: COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer. Primary completion 2026-12-14 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later17

  • Jan 31, 2027
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Tisleizumab(BGB-A317) · Phase 2 · Refractory Solid Cancer Patients Unexposed to Immunotherapy
    NCT07300891: T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy. Primary completion 2027-01-31 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 30, 2027
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Patritumab Deruxtecan · Phase 2 · Solid Tumor, Adult
    NCT06383884: Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion. Primary completion 2027-04-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jul 1, 2027
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Conventional Fractionated IMRT · Phase 3 · Uterine Cervical Neoplasms
    NCT06509724: Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy. Primary completion 2027-07-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 1, 2027
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Osimertinib 80Mg Tab · Phase 2 · Lung Adenocarcinoma
    NCT05528458: Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma. Primary completion 2027-09-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 1, 2027
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Osimertinib 80 MG · Phase 2 · Lung Cancer
    NCT04591002: Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive). Primary completion 2027-09-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2027
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Personalized Ultrafractionated Adaptive Radiotherapy · Phase 2 · Locally Advanced Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma
    NCT07269626: PULSAR in Systemic Therapy for Pancreatic Cancer. Primary completion 2027-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 2028
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    GV1001 Placebo · Phase 3 · Moderate to Severe Alzheimer's Disease
    NCT05303701: GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD). Primary completion 2028-01 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2028
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Belvarafenib · Phase 2 · Primary Brain Tumor; Metastatic Brain Tumor
    NCT07688356: Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors. Primary completion 2028-06-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2028
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Pulse radiation therapy · Phase 2 · Cancer
    NCT07381231: Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors. Primary completion 2028-09-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 30, 2028
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Selinexor · Phase 1 / Phase 2 · B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory
    NCT06552559: Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma. Primary completion 2028-12-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 1, 2029
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Supplementation of magnesium lactate · Phase 2 · Non-small Cell Lung Cancer(NSCLC); EGFR Mutant
    NCT07774520: A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy. Primary completion 2029-06-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2029
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Zastaprazan · Phase 3 · Acute Myocardial Infarction (AMI); Gastrointestinal Bleeding
    NCT07467213: Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction. Primary completion 2029-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 13, 2031
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    SBRT(Stereotatic Body Radiation Therapy) · Phase 3 · Kidney Neoplasm
    NCT06467097: Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma. Primary completion 2031-02-13 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2033
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase. · Phase 2 · Low-to-intermediate-risk Prostate Carcinoma
    NCT06461819: Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L). Primary completion 2033-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2033
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients · Phase 2 · High Risk Prostate Carcinoma
    NCT06461793: Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H). Primary completion 2033-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 31, 2034
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Moderate hypofractionated radiotherapy (Moderate-hypoRT) · Phase 3 · Prostate Cancer
    NCT07500701: Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer. Primary completion 2034-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 2036
    Samsung Biologics Co.,Ltd.(207940.KS)Phase 2/3 readout
    Whole Breast Irradiation · Phase 3 · Breast Cancer; Node-negative Breast Cancer
    NCT07757958: Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast Cancer. Primary completion 2036-06 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗

How Samsung Biologics Co.,Ltd. has moved — past-year price reactions

How binary is 207940.KS? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
1
±10% days
41%
annualized vol
243
trading days
Largest single-day moves
  • +10.1%2026-07-24no matched headline
  • -9.8%2026-03-04no matched headline
  • +9.7%2025-10-15no matched headline
  • -9.1%2025-11-25no matched headline
  • +8.8%2026-06-24no matched headline
  • +8.6%2026-03-05no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Samsung Biologics Co.,Ltd. — active clinical pipeline

Samsung Biologics Co.,Ltd.'s registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

33 assets34 programsPh1 5Ph2 14Ph3 4· 11 post-marketing (Ph4)
AreasOncologyImmunologyNeuroscienceCardiovascularOther
SB27Oncology
Phase 1
Non-small Cell Lung Cancer Stage II
Phase 3
Non-small Cell Lung Cancer Stage IV
GV1001 1.12mgNeuroscience
Phase 3
Moderate to Severe Alzheimer's Disease
Vilanterol and Umeclidinium BromideOther
Phase 3
Chronic Obstructive Pulmonary Disease
ZastaprazanCardiovascular
Phase 3
Acute Myocardial Infarction (AMI)
Avelumab 10 mg/kgOncology · PD-L1
Phase 2
Upper Tract Urothelial Carcinoma
BelvarafenibOncology · RAF1
Phase 2
Primary Brain Tumor
concurrent chemotherapyOncology
Phase 2
Cervical Cancer
GlofitamabOncology · CD20×CD3
Phase 2
Diffuse Large B Cell Lymphoma
Osimertinib 80 MGOncology · EGFR
Phase 2
Lung Cancer
Osimertinib 80Mg TabOncology · EGFR
Phase 2
Lung Adenocarcinoma
Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, AtezolizumabOncology
Phase 2
Premenopausal HR+/HER2- Metastatic Breast Cancer
Patritumab DeruxtecanOncology · HER3 ADC
Phase 2
Solid Tumor, Adult
PneumostemImmunology
Phase 2
Cell Transplantation
RivoceranibOncology
Phase 2
Thymic Epithelial Tumor
SelinexorOncology · XPO1
Phase 2
B-cell Lymphoma Recurrent
Supplementation of magnesium lactateOncology
Phase 2
Non-small Cell Lung Cancer(NSCLC)
Tisleizumab(BGB-A317)Oncology
Phase 2
Refractory Solid Cancer Patients Unexposed to Immunotherapy
trastuzumab, bevacizumab with paclitaxel (triple combination)Oncology
Phase 2
HER2-positive Advanced Gastric Cancer
E303Oncology
Phase 1
Advanced Solid Tumors
ET-STEMNeuroscience
Phase 1
Frontotemporal Dementia
IxekizumabOther · IL-17A
Phase 1
Healthy volunteers
PNEUMOSTEM®Cardiovascular
Phase 1
Pulmonary Arterial Hypertension (PAH)

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.